Background Lennox-Gastaut syndrome (LGS) is a drugresistant pediatric epilepsy characterized by multiple seizure types, including drop attacks (DAs). Palliative procedures such as corpus callosotomy (CC) and vagus nerve stimulation (VNS) may be effective for adequate seizure control in LGS patients who are not candidates for resective surgery. We evaluated the efficacy of the combination of these two procedures for LGS-related seizures. Method Ten patients with LGS (age 3-30 years at VNS implantation) underwent CC and subsequent VNS. We evaluated surgical outcomes, particularly with respect to the efficacy of VNS on seizure reduction rates for different residual seizure types after CC. We compared clinical parameters, including sex, age, seizure duration, history, MRI findings, extent of CC, number of antiepileptic drugs, and neuropsychological states, between VNS responders and non-responders to predict satisfactory seizure outcomes with respect to residual seizures after CC.
Introduction
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset epileptogenic disorder characterized by multiple seizure types with high frequency, mental retardation, and an electroencephalographic (EEG) pattern of diffuse slow spike-and-wave discharges [1] .
LGS accounts for approximately 1-10% of all childhood epilepsies [1] . Tonic seizures (TS), atonic seizures (AS), and atypical absence seizures (AAS) are most commonly observed [1] . Myoclonic seizures (MC), generalized tonic-clonic (GTC), and complex partial seizures may also be present [1] . Characteristic drop attacks (DAs) observed in LGS patients can result from any of the seizure types, particularly from tonic, atonic, and myoclonic seizures [1] . The DAs are severely disabling and limit the quality of life of patients as well as their caregivers.
LGS poorly responds to antiepileptic drugs (AEDs). Previous studies have reported that only 6.7-13.7% of patients achieve seizure freedom with pharmacotherapy [2] . Recently, various treatment options have been administered to LGS patients, including ketogenic diets, vagus nerve stimulation (VNS), corpus callosotomy (CC), and resective surgery [3] . However, the majority of LGS patients are not candidates for resective surgery because of the multifocal characteristics of the disease or the difficulty in localizing a single seizure focus [3] .
VNS is a type of palliative surgery that was approved by the FDA in 1997 as an adjunctive therapy for adults and adolescents over 12 years old who are not eligible for resective surgery. The efficacy of VNS for LGS was recognized in a recent study that reported that 20 of 30 (67%) LGS patients experienced a >50% seizure reduction after VNS [4] . In contrast, Lin and Kwan et al. [5] performed CC in LGS patients to palliate seizures and reported that 31 of 48 (65%) patients experienced a >50% seizure reduction after CC. CC has been the most effective procedure for eliminating or decreasing DAs [6] and is frequently performed in children [6, 7] .
A meta-analysis revealed that seizure freedom is rarely achieved after palliative surgery in patients with LGS; seizure freedom rates were 16% and 5.2% after CC and VNS, respectively [8] . Seizure outcomes of multiple seizure types except for AS observed in LGS, as well as the total number of seizures, did not significantly differ between patients who received VNS vs. CC [8] . A small number of patients in previous studies that evaluated the efficacy of CC for LGS-related seizures underwent subsequent VNS for further seizure control [9] [10] [11] [12] [13] . However, the seizure reduction rates after subsequent VNS for each residual seizure type have not been well studied. Guillamon et al. [14] reported the efficacy of combined CC and VNS in six adults patients (3 patients first underwent VNS followed by CC, and 3 were treated in the reverse order) with intractable epilepsy. These investigators concluded that the combined procedures yielded good results, although the optimal order for performing the two procedures has not yet been defined.
We evaluated surgical outcome in LGS patients who first underwent CC and then VNS, with particular focus on the efficacy of VNS on seizure reduction rates for the different residual seizure types after CC. Furthermore, we compared the clinical parameters between VNS responders (seizure reduction rate, ≥50%) and non-responders (seizure reduction rate, <50%) to better predict satisfactory seizure outcomes for residual seizures after CC.
Methods
This study was approved by the Ethics Committee for Epidemiology of Hiroshima University.
Patient selection
We retrospectively reviewed the clinical records of ten consecutive patients with LGS who first underwent CC and then VNS at Hiroshima University Hospital between January 2012 and April 2014. Inclusion criteria were as follows: multiple seizure types, consistent with LennoxGastaut syndrome, EEG showing diffuse slow spike-wave complexes with or without rapid rhythm during sleep, mental retardation or developmental delay, seizures unacceptable for the patients and parents, and resistance to first-or second-choice antiepileptic drugs. All patients were considered to be ineligible for resective surgery based on presurgical evaluations, including scalp videoelectroencephalography (EEG) and magnetic resonance imaging (MRI). Further diagnostic modalities, i.e., positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([ 18 F]FDG), iodine-123-iomazenil single-photon emission computed tomography (IMZ-SPECT), and magnetoencephalography (MEG), were also performed if necessary. All patients underwent total or anterior CC before VNS. At our hospital, CC is considered first for patients with drop attacks. We performed anterior CC as it was particularly important for patients with relatively preserved intelligence to reduce symptoms of postoperative neurological deficits. If the patients needed further surgical intervention, we performed staged total CC or VNS. The extent of the section was confirmed postoperatively by sagittal MRI. All patients underwent initial CC and, because of residual seizures, subsequently underwent VNS. Patients who had progressive neurological disease or were in poor physical condition that would preclude the surgical implantation procedure were excluded.
VNS parameters
The device was activated 2-3 weeks after implantation of the stimulator. The stimulation was started with the following parameters (output current, 0.25 mA; magnet current, 0.50 mA; pulse width, 500 µs; signal on time, 30 s; signal off time, 5 min) at the first visit. The output current and magnet current intensities were increased by 0.25 mA, as tolerated, until 2.0 mA. After reaching output current maximum intensity, the signal off time was adjusted from 1.8 to 5 min if seizure control was insufficient.
Patient classification based on surgical outcome
We evaluated seizure outcomes at the two follow-up time points, i.e., just before VNS implantation (after CC) and during the 12-month post-VNS period. The seizure frequency for each seizure type was examined by interview with the caregivers (primarily parents). Seizure outcome assessments, except for those for DAs, were made from the modified classification of the VNS-specific outcome scale proposed by McHugh et al. [15] : class I, seizure-free for >3 months before the last follow-up; class II, 80-99% reduction in seizure frequency; class III, 50-79% reduction in seizure frequency; class IV, <50% reduction in seizure frequency; class V, no improvement or exacerbation of seizures. The seizure reduction rate was calculated from the average number of seizures that occurred during the 3 months just before CC and before the aforementioned two time points. The DA outcome after CC was separately assessed and classified as either DA-free or residual.
We evaluated seizure outcomes with respect to the frequency of all seizures at the two time points and to different residual (after CC) seizure types that occurred after VNS (during the 12-month post-VNS period). Patients were classified as responders when they had a ≥50% total seizure reduction rate (class I-III) and as non-responders when they had a <50% total seizure reduction rate (class IV and V).
Comparison of clinical parameters between responders and non-responders
All clinical data were collected by electronic medical records and/or telephone contact from the patients' caregivers, which were primarily the parents. The following clinical parameters were compared between responders and non-responders: sex, age (at seizure onset, CC, and VNS implantation), duration (between seizure onset and CC and between CC and VNS implantation), history of West syndrome, MRI abnormalities, extent of CC (total or not), number of AEDs before VNS, neurological and neuropsychological states (conversation ability, walking ability, and bedridden state), and responders to CC. Conversation ability is defined as the ability to communicate with others, e.g., obeying simple orders, greetings, and expressing demands.
Statistical analysis
For clinical data involving age (at seizure onset, CC, and VNS), duration (between seizure onset and CC, and between CC and VNS), and number of AEDs, unpaired MannWhitney U tests were performed. For other clinical parameters, Fisher's exact test was performed from 2 × 2 contingency tables. P-values <0.05 were considered to be statistically significant. All analyses were performed with SPSS version 16.0. Table 1 shows the clinical profiles of ten patients (6 females), including the history of West syndrome, MRI findings, extent of CC, AEDs before VNS, and neuropsychological state. Ages at seizure onset, CC, and VNS implantation ranged from 1 to 37 months (mean ± SD, 13.3 ± 12.1 months), 1 to 28 years (7.5 ± 8.8 years), and 3 to 30 years (10.7 ± 8.4 years), respectively.
Results

Clinical profiles
Four patients had a history of West syndrome. MRI showed diffuse atrophy in two patients (nos. 3 and 4), extensive or focal abnormalities in three patients (nos. 5, 9, and 10), and negative findings in five patients (nos. 1, 2, 6, 7, and 8). Nine patients underwent total CC prior to VNS [two-staged total CC in 2 patients (nos. 1, 6)] and one (no. 2) underwent anterior two-thirds CC. The number of AEDs before VNS ranged from two to five (3.3 ± 0.9) drugs. With respect to neuropsychological states, conversation and walking abilities before VNS were observed in seven and eight patients, respectively. Two patients (nos. 3 and 7) who were neither able to speak nor walk were bedridden in daily life. Two patients (nos. 1 and 3) were responders to CC.
Seizure types and frequencies before CC
Before CC, all patients had multiple types of seizures, ranging from two to four types (mean, 3.2 types) ( Table 2 ). TSs were the most common and observed in nine patients; AAS occurred in eight patients, AS occurred in seven patients, MC occurred in four patients, atonic or spasm with head drops (HDs) occurred in three patients, and tonic-clonic seizure (TC) occurred in one patient. Nine of ten patients had DAs, which resulted from AS in seven patients and TS and TC in one patient each. All patients had daily seizures. The average total seizure frequency ranged from 4 to 500 per day.
Seizure outcomes for DAs and all seizures after CC (pre-VNS)
Seven of nine (77.8%) patients who had experienced DAs before CC achieved excellent seizure outcomes after CC with regard to DA (patients 1, 4, 5, 6, 8, 9, and 10 were seizurefree). In the two patients whose DAs continued after CC, one with anterior CC experienced a >90% reduction of DAs, and one with total CC experienced no improvement in DAs.
With respect to all seizures including DAs, two of ten (20%) patients had relatively satisfactory seizure outcomes as responders to CC (class II, no. 1; class III, no. 3). The other eight patients were non-responders (class IV, nos. 2, 5, 8; class V, nos. 4, 6, 7, 9, and 10). No patients achieved seizure freedom after CC. In three of ten (30%) patients (nos. 1, 4, and 8), all seizures including DAs had completely remitted, then recurred at 2, 22, and 6 months post-CC, respectively, except for DAs. In contrast, in four of ten (40%) patients (nos. 4, 7, 9, 10), non-DA seizures increased after CC.
After CC (just before VNS), the number of seizure types decreased and ranged from two to four types (mean, 2.8 types). In contrast, seizure frequencies were exacerbated in four (nos. 4, 7, 9, and 10) of the eight non-responders.
Final seizure outcome after VNS
Six of ten (60%) patients had satisfactory seizure outcomes with respect to all residual seizure types as responders after VNS (nos. 1, 2, 4, 6, 8, and 10) ( Table 2 ). Two of the ten (20%) patients were seizure-free at 12 months after VNS. The other four patients were classified as non-responders (nos. 3, 5, 7, and 9). Seizure frequencies decreased to <50% in two patients (nos. 5 and 9) and did not change in two patients (nos. 3 and 7). Among the six VNS responders, five patients (nos. 2, 4, 6, 8, 10) had been non-responders to prior CC with respect to all seizures including DAs.
Final seizure outcome with respect to seizure type after VNS Table 3 shows seizure outcomes at 12 months after VNS for each of the different seizure types that were residual after VNS. TSs were the most common seizure type that was residual after CC. Responses were observed in five of the ten (50%) patients after VNS. AASs were less likely to be controlled with VNS (25% response rate). MC was observed in four patients, two of whom were responders. None of the patients with residual DAs caused by AS responded to VNS. Although the number of patients was small, HD and TC responded well to VNS. Table 4 summarizes the results of statistical analyses of clinical parameters between VNS responders and non-responders. Of the clinical parameters, only the differences in conversation ability were statistically significant (p = 0.033). Patients who responded to VNS after CC could have conversations with others, while non-responders could not. No statistically significant differences were observed for the other clinical parameters, although responders tended to be older at seizure onset compared to non-responders; however, this difference was not statistically significant (p = 0.069). 
Comparison of clinical parameters between VNS responders and non-responders
Complications
In all cases, no permanent morbidities or mortalities related to the two procedures were observed. After CC, all patients experienced acute disconnection syndrome, i.e., mutism and stranguria, which resolved 3-7 days after surgery. After VNS, transient hoarseness was observed in two patients, and coughing only with magnet activation was observed in one patient.
Discussion
Summary of findings VNS was effective for residual seizures regardless of seizure type (except for DAs) after CC in patients with LGS. Even non-responders to prior CC responded to subsequent VNS. Compared to VNS, excellent seizure outcomes for DAs were achieved after CC. Among the clinical parameters, only conversation ability before VNS significantly differed between VNS responders and non-responders.
Combined VNS following CC for LGS-related seizures
Karceski et al. [12] reported the efficacy of VNS in LGS patients (n = 552) as well as in patients who had undergone prior CC (n = 61) and other respective surgeries (n = 8), based on a review of the literature and data from the VNS patient registry. In a group of 483 patients without prior surgeries before VNS, 94 of 145 (65%) patients with a follow-up period of 12 months experienced a ≥50% reduction in seizures. In a group of 61 patients who had undergone prior CC before VNS, 13 of 23 (57 %) patients were responders at 12-month follow-up [12] . In this report, 7 % of patients without prior surgeries were seizurefree at 12 months after VNS compared to 4 % of patients who previously underwent CC [12] . This review revealed the consistent efficacy of administering VNS after CC for LGS-related seizures; however, the seizure reduction rates for each residual seizure type after VNS have not been described. Ben-Menachem et al. [9] . reported the efficacy of VNS with respect to the seizure frequency and severity of GTC, AAS, and AS in five patients with LGS who had undergone previous CC [9] . According to their results, one of the five patients had a >50% reduction and a 50% reduction in seizure frequency and severity, respectively. One patient experienced a 25% reduction in both parameters, two patients had a 25% reduction in just seizure severity, and the remaining patient experienced no changes in either parameter. These authors also reported that subsequent VNS was most effective for GTC and AAS among LGS-related seizures.
In the current study, we evaluated surgical outcomes after VNS with respect to seizure frequency as well as to seizure type. Two of the ten (20%) patients achieved an excellent AAS, atypical absence seizure; AS, atonic seizure; CC, corpus callosotomy; DA, drop attack; HD, head drop; MC, myoclonic seizure; NC, no change; TC, tonic-clonic seizure; TS, tonic seizure; VNS, vagus nerve stimulation; *, **, ***, each patient had temporal seizure remission (2, 22, and 6 months) after CC, and the seizures recurred before VNS seizure outcome (class I by modified McHugh's classification), and six (60%) were responders (class I-III) after subsequent VNS. The present results also revealed add-on effects of VNS for numerous seizure types, including AAS, TS, HD, MC, and TC. Among these seizure types, VNS was most effective for HD and TC. Even non-responders to prior CC responded to subsequent VNS for residual seizures. However, no improvement was observed for atonic seizures (DAs). In four of ten (40%) patients, non-DA seizures increased after CC. Our results also confirmed well-known findings, i.e., that the frequency of some non-DA seizures may increase after callosotomy [16] .
Preoperative predictors of satisfactory surgical outcome of VNS for residual seizures after CC
We evaluated the clinical parameters that may predict VNS responders for residual seizures after prior CC. No reports about the predictors for LGS-related seizures after combined VNS and CC have been published. The present study revealed that only conversation ability before VNS showed a statistically significant difference among also clinical parameters. VNS responders tended to have a late seizure onset, although the difference was not statistically significant. Based on the present results, combined VNS following CC appears to be effective for LGS-related seizures, and these procedures are likely to be feasible, particularly in patients who have the ability to converse.
Sequence of CC and VNS
The ideal order for performing the CC and VNS procedures was not defined in previous studies. VNS is a newly developed procedure. Previous studies commonly used CC for
LGS-related seizures and subsequent VNS for further seizure control. Recently, VNS has tended to be the first choice for [17] . These investigators compared the efficacy of each procedure with respect to AS, TS, MC, AAS, and GTC. CC was very effective in reducing the frequency of AS, while VNS was ineffective (p = 0.004). In contrast, CC was not effective in reducing MC, whereas VNS was (p = 0.017). In the present study, VNS was not effective for residual AS after CC. Based on previous reports and the present results, CC may be better for LGS patients with AS, particularly those resulting in DAs.
Other factors should also be considered when determining the order of the two procedures. Seizure control can be obtained sooner after CC than after VNS. Buoni et al. [18] reported that the response of LGS patients to VNS was delayed for 1 year after implantation.
LGS patients have psychomotor regression. An uncontrollable state and continuing seizure activities can cause a decline in cognitive, social, and behavioral abilities [1] . Early surgical intervention possibly resulting in early efficacy is recommended in such patients with intractable epilepsies [19] . Furthermore, CC may lateralize the epileptic focus in patients with generalized epilepsies, including LGS [16, 20] . Several studies reported electroencephalography findings that changed from generalized or bifocal to focal findings in patients who appeared normal on non-localizing imaging studies [16, 20, 21] . Hur et al. reported [21] that five of seven patients achieved Engel class I or II outcomes by cortical resection after CC, which enabled lateralization of epileptic foci in EEG findings, glucose metabolisms, and cerebral blood flows.
Limitations and future directions
This study has some limitations. First, the number of patients who underwent prior CC and subsequent CC was small; thus, the statistical tests in our study were not very powerful. Moreover, the group was rather heterogeneous in terms of age and CC procedures (total and anterior callosotomy). We are willing to enroll more patients to reveal the precise efficacy of both procedures for LGS-related seizures as well as to assess the qualitative outcomes on the patients' lives. Second, the current follow-up period is short. We are continuing to follow these patients and observe seizure outcomes as much as possible. We need a prospective, randomized study to determine the optimal order for performing both procedures for LGS-related seizures.
Conclusion
Combined VNS and prior CC showed satisfactory seizure outcomes in LGS patients with different seizure types, including DAs. Even non-responders to prior CC responded to subsequent VNS for residual seizures, except for DAs. These procedures may be more likely to be particularly feasible in patients who have speech ability before VNS. CC may be more important for LGS patients with AS, particularly those resulting into DAs.
